Drug Profile
S 14
Alternative Names: S-14Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Araclon Biotech
- Class Small molecules
- Mechanism of Action Phosphodiesterase VII inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Parkinson's-disease in Unknown
- 07 Oct 2016 Phase-I clinical trials in Parkinson's disease (Araclon Biotech pipeline, October 2016)